Introducing ARIA: AI for Regulatory Intelligence & Authoring, our new AI agent, built on everything you already know from NuMantra.
October 27, 2026
admin
A first IND is rarely hard because of any single document. It is hard because one or two people own all of them. The same regulatory lead who interprets Pre-IND feedback is often also pulling stability tables out of a CDMO’s exports, checking whether the Module 3 drug substance narrative matches the batch records, restructuring clinical summaries, and troubleshooting the eCTD backbone the night before the gateway submission.
Larger sponsors spread this across authoring, QC, publishing, and RIM specialists. A five-person biotech RA team, or a team of one, absorbs every handoff and every rework loop personally. This playbook breaks a first IND into the phases where lean teams lose the most time, and shows where automation can take on mechanical work while human review stays in control.
The workload is not simply smaller because the company is smaller. A first IND still has to satisfy the same requirements under 21 CFR Part 312: an organized eCTD with the right CTD modules, internally consistent data, and a technically valid package. What changes is who is available to do the work.
Three pressures dominate:
The approach below treats each of these as a workflow problem rather than a staffing problem.
Most checklists list documents. A more useful one lists data dependencies, because delays come from waiting on inputs, not from writing.
Checklist principle: assign every row an owner, a data-lock date, and a downstream dependency. Module 2 should never be drafted from data that Module 3 or 4 might still change. Sequence the work so summaries are finalized last, and keep a running record of which summary statements rest on which source tables.
For a first IND, CMC content is typically thinner than at NDA stage, but it still has to be accurate, consistent, and traceable. The labor is mostly mechanical: taking tabular data from a LIMS export or CDMO report and turning it into the structured narrative sections that Module 3 expects, in line with ICH M4Q(R1).
Steps 1, 2, and 4 are the strongest automation candidates. ARIA, NuMantra’s AI Regulatory Intelligence and Authoring platform, approaches this through its Author capability, which generates Module 3 narrative from source data such as LIMS exports, stability tables, and batch records, aligned to an approved language library and ICH M4Q(R1).
Two design points matter for a lean team:
Human sign-off remains central. Every draft requires review before it is final. The value is that the reviewer starts from a traceable draft instead of a blank page.
Pre-IND meeting feedback is where timelines most often slip for small teams, because feedback changes the content of documents that were already in progress.
A disciplined response workflow looks like this:
Separate each comment into one of three buckets: (a) requires new data, (b) requires restructuring or re-presentation of existing data, (c) requires clarification only. Only bucket (a) threatens the timeline. Buckets (b) and (c) are authoring and formatting work, which is exactly what can be compressed.
Build a simple impact map: comment, affected CTD section, affected summary statements, owner, due date. Lean teams that skip this step discover downstream inconsistencies during final QC, when fixing them is most expensive.
Revise the underlying source table or narrative first, then regenerate or update the dependent summary text. Editing summaries directly while leaving sources untouched is how contradictions enter a dossier.
Module 2.7 (Clinical Summary) is a frequent casualty of Pre-IND feedback, particularly when the agency asks for different emphasis, clearer rationale, or reorganized presentation of the supporting information. For a first-in-human program the clinical content is limited, but the structure still has to hold together and agree with Module 5 and the protocol.
Restructuring checklist for Module 2.7:
The repetitive part of this work is moving content into the right sections and verifying that placements are correct. ARIA’s Classify capability assigns content from large merged files to the correct CTD sections, with visible reasoning and confidence scores for each assignment. A reviewer can scan the low-confidence assignments first and confirm or correct them, instead of reading every page. As with all ARIA outputs, classifications require human approval.
Publishing problems are disproportionately painful for small teams because they surface last. A document that looks fine in isolation can still fail at the package level through broken hyperlinks, missing or malformed metadata, or XML backbone errors.
Pre-compile validation checklist:
Check | What It Catches
————————————————–
ARIA’s Validate capability runs XML, hyperlink, and metadata validation before compile, and its Publish capability assembles the multi-regional eCTD backbone, packaged per authority (FDA, EMA, PMDA, Health Canada). For a first IND going to FDA, the practical value is catching mechanical defects while there is still time to fix them, rather than after a technical rejection.
Run validation early and repeatedly. Treat the final validation as a confirmation, not a discovery event.
Consider a preclinical oncology biotech with a three-person regulatory team preparing its first IND. The Pre-IND meeting produced comments requesting clearer presentation of the CMC control strategy and a reorganized clinical summary.
Without automation, the team spends the weeks after the meeting re-extracting stability and release data from CDMO exports, rewriting Module 3 narrative by hand, manually re-sorting content into the summary structure, and discovering during final QC that two numbers in the Quality Overall Summary no longer match the updated tables. Publishing begins late, and validation errors are found within days of the target submission date.
With a structured workflow, the team decomposes the Pre-IND comments into data, restructuring, and clarification buckets on day one. Source tables are parsed with layout preserved, narrative drafts are generated with claim-level links to the original tables, and merged documents are classified into CTD sections with confidence scores the reviewer can triage. Validation runs at each milestone rather than once at the end. The people on the team still make every judgment call. They simply stop spending their hours on retyping, re-sorting, and re-checking.
Small teams rarely have a blank slate. Documents live in SharePoint, a CDMO shares data through a LIMS, and a quality system such as TrackWise or an EDMS may already be in place. ARIA is designed to work alongside existing systems, with integrations including Veeva Vault, SharePoint, LIMS, EDMS, TrackWise, and Documentum, rather than requiring a replacement of them. Its Track capability also gives teams submission status and lifecycle tracking, and can serve as a phaseable path off legacy RIM systems as the company grows.
Before placing unpublished program data into any platform, regulatory leaders should ask where it lives and how it is used. ARIA is hosted on AWS with residency and disaster recovery built into the infrastructure. Tenant data is isolated and never pooled across customers, and customer data is never used to train underlying AI models. Role-based access control, audit logs, and encryption in transit and at rest are part of the design, and the platform is built around 21 CFR Part 11 and EU Annex 11 requirements.
A lean team does not need to out-staff a large sponsor to file a clean first IND. It needs to remove the mechanical work, keep every statement traceable to its source, and catch defects early. Automation handles extraction, classification, and validation. Experienced regulatory judgment handles everything that matters.
Book a 15-minute ARIA demo to see how the platform supports a first IND with a lean team.
From expert guidance to actionable regulatory insights, find the support that fits your needs.
Talk to a regulatory expert, or get one IND and eCTD insight each week.
By continuing, you agree to our Privacy Policy.
One short regulatory insight every week. No spam, unsubscribe anytime.
By continuing, you agree to our Privacy Policy.
72h
Share your email and our team will reply within one business day.
By continuing, you agree to our Privacy Policy.
Check stability, impurities, batch records and eCTD links in 5 minutes.
By continuing, you agree to our Privacy Policy